Translation google
Monday, 17 August 2009
VE (SI) - Indonesia is actually already have a technology and the ability to produce anti-virus H1N1 vaccine or flu pigs.
However, development still terkendala funds and the lack of sinergisitas stakeholders. "Technology is there but we terkendala funds. Price vaccine abroad reached USD10 per dose. In fact, to meet the needs of 10% people of Indonesia are expensive to reach USD200 million, or approximately Rp2 trillion, "said Deputy State Minister of Research and Technology Development Sipteknas after Amin Soebandrio scientific seminar" The Development of Vaccines The Future "in the series to HUT-119 in the Bio Farma Bandung, last week.
According to Amin, Indonesia has a H1N1 vaccine seed of the World Health Organization (WHO). However, the government want to make seeds so that the vaccine itself does not always depend on foreign countries. "It is possible vaccine seed produced in Indonesia, but the good survellaince need to identify the virus.
Because until now the virus had not yet been abroad with the same in the country, "said Amin. According to him, the making of H1N1 vaccine is made mandatory to anticipate the spread of swine flu peak. The flu is a phenomenon pig iceberg in terms of the number of sick people who have not yet compared the number of people contracting.
In the United States, the amount of the pain recorded only tens of thousands, but predicted that millions of people are contagious. Director of PT Bio Farma (Persero) Isa Mansyur, said his side need sinergisitas with the academics and the government in developing an anti-H1N1 vaccine.
"Bio Farma though the only vaccine manufacturer in Indonesia and is able to independently conduct research, but we need to work together ABG or academics, businesses, and government kandididat to produce a vaccine," he said. He cite cooperation with Bio Farma Airlangga University and Padjadjaran University in developing a vaccine or anti-virus H5N1 bird flu that has been woven a few years.
Bio Farma also need billions of chicken eggs as the media, but until now only capable of supporting facilities to meet the needs of 100,000 eggs per week. Look in the mirror on that experience, Jesus is very pessimistic that the making of anti-vaccine H1-N1 can be realized in 2010.
Moreover, Bio Farma has not obtained a guarantee from the government purchase of vaccines so that the investment was issued not futile. The government also has not give detailed answers about the amount of vaccine needed and who should be prepared. (rudini)
Monday, 17 August 2009
VE (SI) - Indonesia is actually already have a technology and the ability to produce anti-virus H1N1 vaccine or flu pigs.
However, development still terkendala funds and the lack of sinergisitas stakeholders. "Technology is there but we terkendala funds. Price vaccine abroad reached USD10 per dose. In fact, to meet the needs of 10% people of Indonesia are expensive to reach USD200 million, or approximately Rp2 trillion, "said Deputy State Minister of Research and Technology Development Sipteknas after Amin Soebandrio scientific seminar" The Development of Vaccines The Future "in the series to HUT-119 in the Bio Farma Bandung, last week.
According to Amin, Indonesia has a H1N1 vaccine seed of the World Health Organization (WHO). However, the government want to make seeds so that the vaccine itself does not always depend on foreign countries. "It is possible vaccine seed produced in Indonesia, but the good survellaince need to identify the virus.
Because until now the virus had not yet been abroad with the same in the country, "said Amin. According to him, the making of H1N1 vaccine is made mandatory to anticipate the spread of swine flu peak. The flu is a phenomenon pig iceberg in terms of the number of sick people who have not yet compared the number of people contracting.
In the United States, the amount of the pain recorded only tens of thousands, but predicted that millions of people are contagious. Director of PT Bio Farma (Persero) Isa Mansyur, said his side need sinergisitas with the academics and the government in developing an anti-H1N1 vaccine.
"Bio Farma though the only vaccine manufacturer in Indonesia and is able to independently conduct research, but we need to work together ABG or academics, businesses, and government kandididat to produce a vaccine," he said. He cite cooperation with Bio Farma Airlangga University and Padjadjaran University in developing a vaccine or anti-virus H5N1 bird flu that has been woven a few years.
Bio Farma also need billions of chicken eggs as the media, but until now only capable of supporting facilities to meet the needs of 100,000 eggs per week. Look in the mirror on that experience, Jesus is very pessimistic that the making of anti-vaccine H1-N1 can be realized in 2010.
Moreover, Bio Farma has not obtained a guarantee from the government purchase of vaccines so that the investment was issued not futile. The government also has not give detailed answers about the amount of vaccine needed and who should be prepared. (rudini)
Comment